All Outputs (2)

Individual patient oesophageal cancer 3D models for tailored treatment (2016)
Journal Article
Saunders, J. H., Onion, D., Collier, P., Dorrington, M. S., Argent, R. H., Clarke, P. A., …Grabowska, A. M. (2017). Individual patient oesophageal cancer 3D models for tailored treatment. Oncotarget, 8(15), 24224-24236. https://doi.org/10.18632/oncotarget.12500

Background: A model to predict chemotherapy response would provide a marked clinical benefit, enabling tailored treatment of oesophageal cancer, where less than half of patients respond to the routinely administered chemotherapy.
Methods: Cancer cel... Read More about Individual patient oesophageal cancer 3D models for tailored treatment.

3-dimensional patient-derived lung cancer assays reveal resistance to standards-of-care promoted by stromal cells but sensitivity to histone deacetylase inhibitors (2016)
Journal Article
Onion, D., Argent, R. H., Reece-Smith, A. M., Craze, M. L., Pineda, R. G., Clarke, P. A., …Grabowska, A. M. (2016). 3-dimensional patient-derived lung cancer assays reveal resistance to standards-of-care promoted by stromal cells but sensitivity to histone deacetylase inhibitors. Molecular Cancer Therapeutics, 15(4), https://doi.org/10.1158/1535-7163.MCT-15-0598

There is a growing recognition that current preclinical models do not reflect the tumor microenvironment in cellular, biological, and biophysical content and this may have a profound effect on drug efficacy testing, especially in the era of molecular... Read More about 3-dimensional patient-derived lung cancer assays reveal resistance to standards-of-care promoted by stromal cells but sensitivity to histone deacetylase inhibitors.